BOEHRINGER INGELHEIM CORP. NAMES DIGBY BARRIOS PRESIDENT
BOEHRINGER INGELHEIM CORP. NAMES DIGBY BARRIOS PRESIDENT and CEO, replacing Harvey Sadow, MD, who retired from the company earlier this year. In his new position, Barrios will have principal operating responsibility for Boehringer Ingelheim's total U.S. operations, which include pharmaceuticals, animal health, unit-dose manufacturing and specialty chemicals. Barrios, a former Squibb group VP, is the current president of Boehringer Ingelheim Pharmaceuticals, a job he will retain, as well as exec VP of Boehringer Ingelheim Corp. Of the company's total $500 mil. revenues in the most recent fiscal year, the drug business accounted for about three-fifths, or $320 mil., the firm said. Barrios joined the pharmaceutical unit in 1983 as exec VP and was named an exec VP of the U.S. parent in 1986. Despite his retirement from day-to-day operations, Sadow will continue as chairman of both Boehringer Ingelheim Corp. and Boehringer Ingelheim Pharmaceuticals, the company noted in a March 15 press release. Other announced appointments include Werner Gerstenberg to exec VP-Boehringer Ingelheim Corp., who continues as senior VP-finance and administration and treasurer of the pharmaceutical operation, and Kevin Reddington to VP-mergers & acquisitions of Boehringer Ingelheim Corp. Reddington was most recently VP-finance of the drug unit.
Sign in to continue reading.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: